LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Primary Purpose
Carcinoma, Non-Small-Cell Lung
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
afatinib
erlotinib
Sponsored by

About this trial
This is an interventional treatment trial for Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
Inclusion criteria:
- Diagnosis of advanced stage NSCLC squamous histology.
- Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.
- Eligible to receive 2nd line therapy in the opinion of the investigator.
- Measurable disease according to RECIST 1.1.
- Adequate Performance Status.
- Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.
- Adequate organ function.
- Age = 18 years and above.
- Written informed consent that is consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines.
Exclusion criteria:
- Prior treatment with Epidermal Growth Factor Receptor (EGFR) directed small molecules or antibodies.
- Radiotherapy within 4 weeks prior to randomization.
- Active brain metastases .
- Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
- Known pre-existing interstitial lung disease.
- Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom
- Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
- Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
Female patients of childbearing potential (see Section 4.2.3.3) who:
- are nursing or
- are pregnant or
- are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
- Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
- Known or suspected active drug or alcohol abuse in the opinion of the investigator.
- Any contraindications for therapy with afatinib or erlotinib.
- Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.
- Major surgery within 4 weeks of starting study treatment.
- Prior participation in an afatinib clinical study, even if not assigned to afatinib.
- Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).
- Patients without Progression of their lung cancer.
Sites / Locations
- Ironwood Cancer and Research Centers
- University of California
- Sutter Medical Group
- Boca Raton Reginl Hospital-Lynn Cancer Institute
- Memorial Healthcare System
- Cancer Care of North Florida, PA
- Illinois Cancer Specialists
- Orchard Healthcare Research Inc
- University of Louisville
- West Jefferson General Hospital and Cancer Clinic
- Lahey Clinic
- Commonwealth Hematology-Oncology, PC
- Karmanos Cancer Institute
- Washington University School of Medicine
- Billings Clinic Cancer Center
- Montefiore Medical Center
- Montefiore Medical Center
- Queens Medical Associates
- SUNY Upstate Medical University
- Cleveland Clinic
- The Ohio State University Wexner Medical Center
- Mid Ohio Oncology/Hematology, Inc
- Kaiser Permanente Northwest
- Oncology Hematology Associates of Norhtern Pennsylvania, PC
- Kimmel Cancer Center
- Temple University Cancer Center
- Spartanburg Regional Medical Center
- Cancer Center of Cookeville Regional Medical Center
- Paris Cancer Center (PCC), Texas Oncology
- Cancer Therapy and Research at UTHSCSA
- Fletcher Allen Health Care
- Blue Ridge Cancer Care
- Virginia Oncology Associates
- Instituto Medico Especializado Alexander Fleming
- Instituto Oncologico de Cordoba
- Clínica Colombo S.A.
- Centro Oncologico de Rosario
- Centro Oncologico CAIPO
- Medical University of Innsbruck
- LKH Leoben
- AKH d. Stadt Linz, Pulmologie
- SMZ Baumgartner Hoehe Otto Wagner Spital
- BC Cancer Agency - Fraser Valley Centre
- Kingston General Hospital
- The Ottawa Hospital
- Royal Victoria Hospital
- Montreal General Hospital - McGill University Health Centre
- Centro Oncologico Antofagasta
- Instituto de Terapias Oncologicas Providencia
- Centro Internacional de Estudios Clinicos - CIEC
- Orlandi Oncologia
- Beijing Cancer Hospital
- Beijing Hospital
- First Hospital of Jilin University
- Xiangya Hospital, Central South University
- Sun Yat-Sen University Cancer Center
- the 81th Hospital of PLA
- Jiangsu Cancer Hospital
- Shanghai Chest Hospital
- Shanghai Pulmonary Hospital
- Herlev Hospital
- Næstved Sygehus
- Odense Universitetshospital
- HOP d'Angers
- INS Bergonié
- HOP Côte de Nacre
- HOP de Chauny
- HOP Gabriel-Montpied
- HOP de Creteil, Pneumo, Creteil
- HOP Le Mans
- CTR Oscar Lambret, Cancéro, Lille
- HOP Calmette
- HOP Nord
- INS Paoli-Calmettes
- HOP de Mulhouse, Onco, Mulhouse
- HOP Cochin
- HOP Val de Grâce, Onco, Paris
- INS Jean Godinot, Onco, Reims
- HOP de Rennes, Pneumo, Rennes
- HOP Saint Quentin, Onco, Saint Quentin
- HOP Civil
- HOP Foch
- INS Gustave Roussy
- Zentralklinik Bad Berka GmbH
- Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
- Klinikum Esslingen GmbH
- Universitätsklinikum Frankfurt
- Universitätsklinikum Freiburg
- Universitätsklinikum Hamburg-Eppendorf
- Lungenklinik Hemer
- Universitätsklinikum Mannheim GmbH
- Universitätsklinikum Münster
- Mathias-Spital Rheine
- "Hippokratio" Hospital of Athens, 2nd Internal Medicine Clin
- General Hospital of Chest Diseases Sotiria
- University General Hospital of Heraklion
- University Hospital of Larisa, Oncology Clinic
- General Hospital of Larissa
- Metropolitan Hospital, Oncology Clinic
- General Hospital "G. Papageorgiou"
- National Koranyi TBC and Pulm. Internal Med. Clinic
- Semmelweis University
- Institute of Chest Diseases Csongrad County,Dpt. Pulmonology
- Pulmonology Institute of Veszprem County, Farkasgyepu
- Aladar Petz County Teaching Hospital, Dept. Pulmonology
- Lung Hospital of Matra, Dept. Pulmonology
- Josa Andras Korhaz, Nyiregyhaza
- University of Pecs, 1st internal Med. Dept., Pulmonology
- Pest County Lung Hospital, Department No. 3
- Vikram Hospital
- V S Hospital
- Dr. Kamakshi Memorial Hospital
- Sri Ramachandra Medical College & Research Institute
- M.S. Patel Cancer Hospital
- B. P .Poddar Hospital & Medical Research Ltd.
- Tata Memorial Hospital
- Ruby Hall Clinic
- St James's Hospital
- P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna
- ASST di Cremona
- Spedali Riuniti di Livorno
- Istituto Nazionale Tumori Fondazione Pascale
- Istituto Oncologico Veneto IRCCS
- Azienda Ospedaliera di Parma
- Azienda Ospedaliera Universitaria Pisana
- Istituto Clinico Humanitas
- Ospedale San Vincenzo
- Ospedale Molinette, AO Città della Salute e della
- A. O. S. Maria della Misericordia
- Chungbuk National University Hospital
- Gachon University Gil Medical Center
- Gyeongsang National University Hospital
- Seoul National University Bundang Hospital
- Asan Medical Center
- Samsung Medical Center
- The Catholic University of Korea, Seoul St.Mary's Hospital
- The Catholic University of Korea, St.Vincent's Hospital
- Ulsan University Hospital
- Instituto Nacional de Cancerologia
- Hospital y Clínica OCA S. A. de C. V.
- Centro Hemato-Oncologico Privado de Toluca S.A. de C.V.
- Jeroen Bosch Ziekenhuis-Hertogenbosch
- Rijnstate Hospital
- Amphia Ziekenhuis
- Catharina Ziekenhuis
- METC Academisch Ziekenhuis Maastricht/Universiteit van Maastricht
- St. Antonius ziekenhuis, locatie Nieuwegein
- Erasmus Medisch Centrum
- CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
- CHLN, EPE - Hospital de Santa Maria
- IPO Lisboa Francisco Gentil, EPE
- IPO Porto Francisco Gentil, EPE
- Centro Hospitalar São João,EPE
- Centro Hospitalar de Vila Nova de Gaia
- National Cancer Centre
- Johns Hopkins Singapore International Medical Centre
- Hospital A Coruña
- Hospital Vall d'Hebron
- Hospital Santa Creu i Sant Pau
- Hospital Clínico San Carlos
- Hospital La Paz
- Hospital Regional Universitario de Málaga
- Hospital Virgen de la Victoria
- Hospital Clínico de Valencia
- Hospital Clínico Universitario Lozano Blesa
- Chang Gung Memorial Hospital Chiayi
- Buddhist Tzu Chi General Hospital
- Kaohsiung Chang Gung Memorial Hospital
- China Medical University Hospital
- Taichung Veterans General Hospital
- National Taiwan University Hospital
- Koo Foundation Sun Yet-Sen Cancer Center
- Taipe Veterans General Hospital
- Chang Gung Memorial Hospital(TaoYuan)
- Akdeniz Universitesi Tip Fakultesi
- Uludag Universitesi Tip Fakultesi, Bursa
- Dicle Universitesi Tip Fakultesi
- Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali
- Kartal Egitim Ve Arastirma Hastanesi
- Yedikule Gog. Hst. EAH
- Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali
- Dr.Suat Seren EAH
- Queen Elizabeth Hospital
- Royal Devon and Exeter Hospital
- Beatson West of Scotland Cancer Centre
- Harrogate District Hospital
- Royal Free Hospital
- The Royal Marsden Hospital
- Maidstone Hospital, Kent Oncology Centre
- Nottingham City Hospital
- Scarborough Hospital
- The Royal Marsden Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Afatinib
Erlotinib
Arm Description
Patients receive afatinib tablets once daily
Patients receive erlotinib tablets once daily
Outcomes
Primary Outcome Measures
Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1
Progression Free Survival (PFS) was defined as the time from randomization to disease progression (or death if the patient died before progression) by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. RECIST is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize") or worsen ("progress") during treatment. Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Secondary Outcome Measures
Overall Survival
Overall Survival is defined as the time from randomisation to death. It was a key secondary endpoint.
Number of Participants With Objective Response According to RECIST 1.1
A patient with a best overall response of Complete Responder (CR) or Partial Responder (PR) was considered to show objective response to study medication. For patients with an objective response, time to objective response was defined as the time from randomization to the first objective response; duration of objective response was defined as the time from the first objective response to progression (or death if the patient died before progression). Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Number of Participants With Disease Control According to RECIST 1.1
Disease control was assessed based on Independent Radiologic Review (IRR) and investigator assessment. A patient with a best overall response of CR, PR, or Stable Disease (SD) was considered to have disease control. Patients with no baseline target lesions who had no evidence of disease progression in their non-target lesions and had no new lesions were considered to have disease control. Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Tumour Shrinkage
Maximum percentage decrease from baseline in the sum of target lesion diameters following independent review. The change in the size (i.e. the sum of diameters (SOD)) of target lesions from baseline was derived. Tumour shrinkage for each patient was measured (based on Independent Radiologic Review (IRR)) as the minimum SOD of target lesions after randomisation.
A negative percentage indicates decrease from baseline; positive numbers indicate an increase of tumour size. The mean maximum decrease from baseline of +5 and +9.4 reflect an average increase in tumour size.
Post-baseline mean is adjusted for baseline sum of diameters and race.
Number of Participants With Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire
Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the european organization for research and treatment of cancer (eortc) quality of life questionnaire (QLQ-C30) questionnaire and its lung cancer specific supplementary module EORTC QLQ-LC13 and the EQ-5D health status self-assessment questionnaire. The questionnaires were assessed at the first visit of each treatment course, at end of treatment (EOT) and follow up prior to clinical assessment. The results displayed show number of patients with improvement in the relevant criteria. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: The number of patients that were improved: Change in cough; dyspnoea and pain scores over time.
Summary of Time to Deterioration in Coughing, Dyspnoea and Pain.
Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: Time to deterioration.
Change in Score Over Time in Coughing,Dyspnoea and Pain
Health related quality of life (HRQoL) was measured with the following multi dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of change in score over time, adjusted for baseline score and race.
Questionnaires have items relating to Cough, Dyspnoea and Pain. Overall Scores are transformed to a standardised scale of 0 to 100 with the larger value indicating a worse outcome. A change of (+/-) 10 points is considered to be relevant.
The change in cough, dyspnea and pain will be assessed using a mixed effects growth curve model with the average profile over time for each endpoint described by a piecewise linear model (presented as post baseline in data table). Post-baseline mean is adjusted for baseline and race.
Full Information
NCT ID
NCT01523587
First Posted
January 30, 2012
Last Updated
February 8, 2019
Sponsor
Boehringer Ingelheim
1. Study Identification
Unique Protocol Identification Number
NCT01523587
Brief Title
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Official Title
LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
March 5, 2012 (Actual)
Primary Completion Date
October 21, 2013 (Actual)
Study Completion Date
December 27, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Non-Small-Cell Lung
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
795 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Afatinib
Arm Type
Experimental
Arm Description
Patients receive afatinib tablets once daily
Arm Title
Erlotinib
Arm Type
Active Comparator
Arm Description
Patients receive erlotinib tablets once daily
Intervention Type
Drug
Intervention Name(s)
afatinib
Intervention Description
Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
erlotinib
Intervention Description
erlotinib taken once daily
Primary Outcome Measure Information:
Title
Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1
Description
Progression Free Survival (PFS) was defined as the time from randomization to disease progression (or death if the patient died before progression) by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. RECIST is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize") or worsen ("progress") during treatment. Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time Frame
First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Secondary Outcome Measure Information:
Title
Overall Survival
Description
Overall Survival is defined as the time from randomisation to death. It was a key secondary endpoint.
Time Frame
From first drug administration from 9 April 2012 until study closure on 27 Dec 2017 (approximately 2089 days).
Title
Number of Participants With Objective Response According to RECIST 1.1
Description
A patient with a best overall response of Complete Responder (CR) or Partial Responder (PR) was considered to show objective response to study medication. For patients with an objective response, time to objective response was defined as the time from randomization to the first objective response; duration of objective response was defined as the time from the first objective response to progression (or death if the patient died before progression). Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time Frame
First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Title
Number of Participants With Disease Control According to RECIST 1.1
Description
Disease control was assessed based on Independent Radiologic Review (IRR) and investigator assessment. A patient with a best overall response of CR, PR, or Stable Disease (SD) was considered to have disease control. Patients with no baseline target lesions who had no evidence of disease progression in their non-target lesions and had no new lesions were considered to have disease control. Per RECIST v1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time Frame
First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Title
Tumour Shrinkage
Description
Maximum percentage decrease from baseline in the sum of target lesion diameters following independent review. The change in the size (i.e. the sum of diameters (SOD)) of target lesions from baseline was derived. Tumour shrinkage for each patient was measured (based on Independent Radiologic Review (IRR)) as the minimum SOD of target lesions after randomisation.
A negative percentage indicates decrease from baseline; positive numbers indicate an increase of tumour size. The mean maximum decrease from baseline of +5 and +9.4 reflect an average increase in tumour size.
Post-baseline mean is adjusted for baseline sum of diameters and race.
Time Frame
First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Title
Number of Participants With Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire
Description
Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the european organization for research and treatment of cancer (eortc) quality of life questionnaire (QLQ-C30) questionnaire and its lung cancer specific supplementary module EORTC QLQ-LC13 and the EQ-5D health status self-assessment questionnaire. The questionnaires were assessed at the first visit of each treatment course, at end of treatment (EOT) and follow up prior to clinical assessment. The results displayed show number of patients with improvement in the relevant criteria. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: The number of patients that were improved: Change in cough; dyspnoea and pain scores over time.
Time Frame
From first drug administration from 9 April 2012 until study closure on 27 Dec 2017 (approximately 2089 days).
Title
Summary of Time to Deterioration in Coughing, Dyspnoea and Pain.
Description
Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: Time to deterioration.
Time Frame
From first drug administration from 9 April 2012 until study closure on 27 Dec 2017 (approximately 2089 days).
Title
Change in Score Over Time in Coughing,Dyspnoea and Pain
Description
Health related quality of life (HRQoL) was measured with the following multi dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of change in score over time, adjusted for baseline score and race.
Questionnaires have items relating to Cough, Dyspnoea and Pain. Overall Scores are transformed to a standardised scale of 0 to 100 with the larger value indicating a worse outcome. A change of (+/-) 10 points is considered to be relevant.
The change in cough, dyspnea and pain will be assessed using a mixed effects growth curve model with the average profile over time for each endpoint described by a piecewise linear model (presented as post baseline in data table). Post-baseline mean is adjusted for baseline and race.
Time Frame
From first drug administration from 9 April 2012 until study closure on 27 Dec 2017 (approximately 2089 days).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Diagnosis of advanced stage NSCLC squamous histology.
Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.
Eligible to receive 2nd line therapy in the opinion of the investigator.
Measurable disease according to RECIST 1.1.
Adequate Performance Status.
Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.
Adequate organ function.
Age = 18 years and above.
Written informed consent that is consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines.
Exclusion criteria:
Prior treatment with Epidermal Growth Factor Receptor (EGFR) directed small molecules or antibodies.
Radiotherapy within 4 weeks prior to randomization.
Active brain metastases .
Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
Known pre-existing interstitial lung disease.
Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom
Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
Female patients of childbearing potential (see Section 4.2.3.3) who:
are nursing or
are pregnant or
are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
Known or suspected active drug or alcohol abuse in the opinion of the investigator.
Any contraindications for therapy with afatinib or erlotinib.
Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.
Major surgery within 4 weeks of starting study treatment.
Prior participation in an afatinib clinical study, even if not assigned to afatinib.
Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).
Patients without Progression of their lung cancer.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
Ironwood Cancer and Research Centers
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
University of California
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Sutter Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Boca Raton Reginl Hospital-Lynn Cancer Institute
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
Memorial Healthcare System
City
Hollywood
State/Province
Florida
ZIP/Postal Code
22021
Country
United States
Facility Name
Cancer Care of North Florida, PA
City
Lake City
State/Province
Florida
ZIP/Postal Code
32024
Country
United States
Facility Name
Illinois Cancer Specialists
City
Niles
State/Province
Illinois
ZIP/Postal Code
60714
Country
United States
Facility Name
Orchard Healthcare Research Inc
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60076
Country
United States
Facility Name
University of Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
West Jefferson General Hospital and Cancer Clinic
City
Marrero
State/Province
Louisiana
ZIP/Postal Code
70072
Country
United States
Facility Name
Lahey Clinic
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
Commonwealth Hematology-Oncology, PC
City
Lawrence
State/Province
Massachusetts
ZIP/Postal Code
01841
Country
United States
Facility Name
Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Billings Clinic Cancer Center
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
Queens Medical Associates
City
Fresh Meadows
State/Province
New York
ZIP/Postal Code
11366
Country
United States
Facility Name
SUNY Upstate Medical University
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
The Ohio State University Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43201
Country
United States
Facility Name
Mid Ohio Oncology/Hematology, Inc
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43219
Country
United States
Facility Name
Kaiser Permanente Northwest
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States
Facility Name
Oncology Hematology Associates of Norhtern Pennsylvania, PC
City
DuBois
State/Province
Pennsylvania
ZIP/Postal Code
15801
Country
United States
Facility Name
Kimmel Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Temple University Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Spartanburg Regional Medical Center
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Cancer Center of Cookeville Regional Medical Center
City
Cookeville
State/Province
Tennessee
ZIP/Postal Code
38501
Country
United States
Facility Name
Paris Cancer Center (PCC), Texas Oncology
City
Paris
State/Province
Texas
ZIP/Postal Code
75460
Country
United States
Facility Name
Cancer Therapy and Research at UTHSCSA
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Fletcher Allen Health Care
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Blue Ridge Cancer Care
City
Christiansburg
State/Province
Virginia
ZIP/Postal Code
24382
Country
United States
Facility Name
Virginia Oncology Associates
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Instituto Medico Especializado Alexander Fleming
City
Ciudad Autonoma de Bs As
ZIP/Postal Code
C1426ANZ
Country
Argentina
Facility Name
Instituto Oncologico de Cordoba
City
Cordoba
ZIP/Postal Code
X5000HXL
Country
Argentina
Facility Name
Clínica Colombo S.A.
City
Cordoba
ZIP/Postal Code
X5002AOQ
Country
Argentina
Facility Name
Centro Oncologico de Rosario
City
Rosario
ZIP/Postal Code
S2000KZE
Country
Argentina
Facility Name
Centro Oncologico CAIPO
City
San Miguel de Tucuman
ZIP/Postal Code
T4000GTB
Country
Argentina
Facility Name
Medical University of Innsbruck
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
LKH Leoben
City
Leoben
ZIP/Postal Code
8700
Country
Austria
Facility Name
AKH d. Stadt Linz, Pulmologie
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
SMZ Baumgartner Hoehe Otto Wagner Spital
City
Wien
ZIP/Postal Code
1140
Country
Austria
Facility Name
BC Cancer Agency - Fraser Valley Centre
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V 1Z2
Country
Canada
Facility Name
Kingston General Hospital
City
Kingston
State/Province
Ontario
ZIP/Postal Code
K7L 5P9
Country
Canada
Facility Name
The Ottawa Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Royal Victoria Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
Facility Name
Montreal General Hospital - McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3G 1A4
Country
Canada
Facility Name
Centro Oncologico Antofagasta
City
Antofagasta
ZIP/Postal Code
1720421
Country
Chile
Facility Name
Instituto de Terapias Oncologicas Providencia
City
Providencia, Santiago
ZIP/Postal Code
7501088
Country
Chile
Facility Name
Centro Internacional de Estudios Clinicos - CIEC
City
Recoleta, Santiago De Chile
ZIP/Postal Code
8420383
Country
Chile
Facility Name
Orlandi Oncologia
City
Vitacura
ZIP/Postal Code
7630457
Country
Chile
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100036
Country
China
Facility Name
Beijing Hospital
City
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
First Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130021
Country
China
Facility Name
Xiangya Hospital, Central South University
City
Changsha
ZIP/Postal Code
410008
Country
China
Facility Name
Sun Yat-Sen University Cancer Center
City
Guangzhou
ZIP/Postal Code
510060
Country
China
Facility Name
the 81th Hospital of PLA
City
Nanjing
ZIP/Postal Code
210002
Country
China
Facility Name
Jiangsu Cancer Hospital
City
Nanjing
ZIP/Postal Code
210009
Country
China
Facility Name
Shanghai Chest Hospital
City
Shanghai
ZIP/Postal Code
200030
Country
China
Facility Name
Shanghai Pulmonary Hospital
City
Shanghai
ZIP/Postal Code
200433
Country
China
Facility Name
Herlev Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Næstved Sygehus
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Facility Name
Odense Universitetshospital
City
Odense C
ZIP/Postal Code
5000
Country
Denmark
Facility Name
HOP d'Angers
City
Angers
ZIP/Postal Code
49 933
Country
France
Facility Name
INS Bergonié
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
HOP Côte de Nacre
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
HOP de Chauny
City
Chauny
ZIP/Postal Code
02303
Country
France
Facility Name
HOP Gabriel-Montpied
City
Clermont Ferrand
ZIP/Postal Code
63003
Country
France
Facility Name
HOP de Creteil, Pneumo, Creteil
City
Creteil
ZIP/Postal Code
94010
Country
France
Facility Name
HOP Le Mans
City
Le Mans
ZIP/Postal Code
72037
Country
France
Facility Name
CTR Oscar Lambret, Cancéro, Lille
City
Lille
ZIP/Postal Code
59020
Country
France
Facility Name
HOP Calmette
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
HOP Nord
City
Marseille Cedex 20
ZIP/Postal Code
13915
Country
France
Facility Name
INS Paoli-Calmettes
City
Marseille
ZIP/Postal Code
13273
Country
France
Facility Name
HOP de Mulhouse, Onco, Mulhouse
City
Mulhouse
ZIP/Postal Code
68070
Country
France
Facility Name
HOP Cochin
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
HOP Val de Grâce, Onco, Paris
City
Paris
ZIP/Postal Code
75230
Country
France
Facility Name
INS Jean Godinot, Onco, Reims
City
Reims
ZIP/Postal Code
51056
Country
France
Facility Name
HOP de Rennes, Pneumo, Rennes
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
HOP Saint Quentin, Onco, Saint Quentin
City
Saint Quentin
ZIP/Postal Code
02321
Country
France
Facility Name
HOP Civil
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
HOP Foch
City
Suresnes
ZIP/Postal Code
92151
Country
France
Facility Name
INS Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Facility Name
Zentralklinik Bad Berka GmbH
City
Bad Berka
ZIP/Postal Code
99437
Country
Germany
Facility Name
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Klinikum Esslingen GmbH
City
Esslingen
ZIP/Postal Code
73730
Country
Germany
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt am Main
ZIP/Postal Code
60590
Country
Germany
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Lungenklinik Hemer
City
Hemer
ZIP/Postal Code
58675
Country
Germany
Facility Name
Universitätsklinikum Mannheim GmbH
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Universitätsklinikum Münster
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Mathias-Spital Rheine
City
Rheine
ZIP/Postal Code
48431
Country
Germany
Facility Name
"Hippokratio" Hospital of Athens, 2nd Internal Medicine Clin
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
General Hospital of Chest Diseases Sotiria
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
University General Hospital of Heraklion
City
Heraklion
ZIP/Postal Code
71110
Country
Greece
Facility Name
University Hospital of Larisa, Oncology Clinic
City
Larisa
ZIP/Postal Code
41110
Country
Greece
Facility Name
General Hospital of Larissa
City
Larisa
ZIP/Postal Code
41221
Country
Greece
Facility Name
Metropolitan Hospital, Oncology Clinic
City
Neo Faliro, Athens
ZIP/Postal Code
18547
Country
Greece
Facility Name
General Hospital "G. Papageorgiou"
City
Thessaloniki
ZIP/Postal Code
56429
Country
Greece
Facility Name
National Koranyi TBC and Pulm. Internal Med. Clinic
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Facility Name
Semmelweis University
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Institute of Chest Diseases Csongrad County,Dpt. Pulmonology
City
Deszk
ZIP/Postal Code
6772
Country
Hungary
Facility Name
Pulmonology Institute of Veszprem County, Farkasgyepu
City
Farkasgyepü
ZIP/Postal Code
8582
Country
Hungary
Facility Name
Aladar Petz County Teaching Hospital, Dept. Pulmonology
City
Györ
ZIP/Postal Code
9023
Country
Hungary
Facility Name
Lung Hospital of Matra, Dept. Pulmonology
City
Matrahaza
ZIP/Postal Code
3233
Country
Hungary
Facility Name
Josa Andras Korhaz, Nyiregyhaza
City
Nyiregyhaza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
University of Pecs, 1st internal Med. Dept., Pulmonology
City
Pecs
ZIP/Postal Code
7623
Country
Hungary
Facility Name
Pest County Lung Hospital, Department No. 3
City
Törökbalint
ZIP/Postal Code
2045
Country
Hungary
Facility Name
Vikram Hospital
City
Bangalore
ZIP/Postal Code
560052
Country
India
Facility Name
V S Hospital
City
Chennai
ZIP/Postal Code
600031
Country
India
Facility Name
Dr. Kamakshi Memorial Hospital
City
Chennai
ZIP/Postal Code
600100
Country
India
Facility Name
Sri Ramachandra Medical College & Research Institute
City
Chennai
ZIP/Postal Code
600116
Country
India
Facility Name
M.S. Patel Cancer Hospital
City
Karamsad
ZIP/Postal Code
388325
Country
India
Facility Name
B. P .Poddar Hospital & Medical Research Ltd.
City
Kolkata, West Bengal
ZIP/Postal Code
700053
Country
India
Facility Name
Tata Memorial Hospital
City
Mumbai
ZIP/Postal Code
400012
Country
India
Facility Name
Ruby Hall Clinic
City
Pune
ZIP/Postal Code
411001
Country
India
Facility Name
St James's Hospital
City
Dublin 8
ZIP/Postal Code
Dublin
Country
Ireland
Facility Name
P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna
City
Bologna
ZIP/Postal Code
40139
Country
Italy
Facility Name
ASST di Cremona
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
Spedali Riuniti di Livorno
City
Livorno
ZIP/Postal Code
57100
Country
Italy
Facility Name
Istituto Nazionale Tumori Fondazione Pascale
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Istituto Oncologico Veneto IRCCS
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Azienda Ospedaliera di Parma
City
Parma
ZIP/Postal Code
43100
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Pisana
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Facility Name
Istituto Clinico Humanitas
City
Rozzano (MI)
ZIP/Postal Code
20089
Country
Italy
Facility Name
Ospedale San Vincenzo
City
Taormina (ME)
ZIP/Postal Code
98039
Country
Italy
Facility Name
Ospedale Molinette, AO Città della Salute e della
City
Torino
ZIP/Postal Code
10126
Country
Italy
Facility Name
A. O. S. Maria della Misericordia
City
Udine
ZIP/Postal Code
33100
Country
Italy
Facility Name
Chungbuk National University Hospital
City
Cheongju
ZIP/Postal Code
361-711
Country
Korea, Republic of
Facility Name
Gachon University Gil Medical Center
City
Incheon
ZIP/Postal Code
405-760
Country
Korea, Republic of
Facility Name
Gyeongsang National University Hospital
City
Jinju
ZIP/Postal Code
660-702
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
130-710
Country
Korea, Republic of
Facility Name
The Catholic University of Korea, Seoul St.Mary's Hospital
City
Seoul
ZIP/Postal Code
137-701
Country
Korea, Republic of
Facility Name
The Catholic University of Korea, St.Vincent's Hospital
City
Suwon
ZIP/Postal Code
442-723
Country
Korea, Republic of
Facility Name
Ulsan University Hospital
City
Ulsan
ZIP/Postal Code
682-714
Country
Korea, Republic of
Facility Name
Instituto Nacional de Cancerologia
City
Mexico
ZIP/Postal Code
14080
Country
Mexico
Facility Name
Hospital y Clínica OCA S. A. de C. V.
City
Monterrey
ZIP/Postal Code
64000
Country
Mexico
Facility Name
Centro Hemato-Oncologico Privado de Toluca S.A. de C.V.
City
Toluca
ZIP/Postal Code
50080
Country
Mexico
Facility Name
Jeroen Bosch Ziekenhuis-Hertogenbosch
City
's-HERTOGENBOSCH
ZIP/Postal Code
5223 GZ
Country
Netherlands
Facility Name
Rijnstate Hospital
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands
Facility Name
Amphia Ziekenhuis
City
Breda
ZIP/Postal Code
4818 CK
Country
Netherlands
Facility Name
Catharina Ziekenhuis
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
METC Academisch Ziekenhuis Maastricht/Universiteit van Maastricht
City
Maastricht
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Name
St. Antonius ziekenhuis, locatie Nieuwegein
City
Nieuwegein
ZIP/Postal Code
3435 CM
Country
Netherlands
Facility Name
Erasmus Medisch Centrum
City
Rotterdam
ZIP/Postal Code
3015 CD
Country
Netherlands
Facility Name
CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
City
Coimbra
ZIP/Postal Code
3041-801
Country
Portugal
Facility Name
CHLN, EPE - Hospital de Santa Maria
City
Lisboa
ZIP/Postal Code
1064-035
Country
Portugal
Facility Name
IPO Lisboa Francisco Gentil, EPE
City
Lisboa
ZIP/Postal Code
1099-023
Country
Portugal
Facility Name
IPO Porto Francisco Gentil, EPE
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Centro Hospitalar São João,EPE
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Facility Name
Centro Hospitalar de Vila Nova de Gaia
City
Vila Nova de Gaia
ZIP/Postal Code
4434-502
Country
Portugal
Facility Name
National Cancer Centre
City
Singapore
ZIP/Postal Code
169610
Country
Singapore
Facility Name
Johns Hopkins Singapore International Medical Centre
City
Singapore
ZIP/Postal Code
308433
Country
Singapore
Facility Name
Hospital A Coruña
City
A Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Hospital Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Hospital Clínico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Regional Universitario de Málaga
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Virgen de la Victoria
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Clínico de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Hospital Clínico Universitario Lozano Blesa
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Chang Gung Memorial Hospital Chiayi
City
Chiayi
ZIP/Postal Code
613
Country
Taiwan
Facility Name
Buddhist Tzu Chi General Hospital
City
Chiayi
ZIP/Postal Code
622
Country
Taiwan
Facility Name
Kaohsiung Chang Gung Memorial Hospital
City
Kaohsiung
ZIP/Postal Code
833
Country
Taiwan
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Facility Name
Taichung Veterans General Hospital
City
Taichung
ZIP/Postal Code
407
Country
Taiwan
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Facility Name
Koo Foundation Sun Yet-Sen Cancer Center
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Facility Name
Taipe Veterans General Hospital
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Facility Name
Chang Gung Memorial Hospital(TaoYuan)
City
Taoyuan
ZIP/Postal Code
330
Country
Taiwan
Facility Name
Akdeniz Universitesi Tip Fakultesi
City
Antalya
ZIP/Postal Code
07070
Country
Turkey
Facility Name
Uludag Universitesi Tip Fakultesi, Bursa
City
Bursa
ZIP/Postal Code
16045
Country
Turkey
Facility Name
Dicle Universitesi Tip Fakultesi
City
Diyarbakir
Country
Turkey
Facility Name
Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali
City
Gaziantep
ZIP/Postal Code
27310
Country
Turkey
Facility Name
Kartal Egitim Ve Arastirma Hastanesi
City
Istanbul
Country
Turkey
Facility Name
Yedikule Gog. Hst. EAH
City
Istanbul
Country
Turkey
Facility Name
Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Facility Name
Dr.Suat Seren EAH
City
Izmir
ZIP/Postal Code
35120
Country
Turkey
Facility Name
Queen Elizabeth Hospital
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
Royal Devon and Exeter Hospital
City
Exeter
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Facility Name
Beatson West of Scotland Cancer Centre
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Facility Name
Harrogate District Hospital
City
Harrogate
ZIP/Postal Code
HG2 7SX
Country
United Kingdom
Facility Name
Royal Free Hospital
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Facility Name
The Royal Marsden Hospital
City
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Maidstone Hospital, Kent Oncology Centre
City
Maidstone
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Facility Name
Nottingham City Hospital
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Scarborough Hospital
City
Scarborough
ZIP/Postal Code
YO12 6QL
Country
United Kingdom
Facility Name
The Royal Marsden Hospital
City
Sutton
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
30573970
Citation
Lu S, Li W, Zhou C, Hu CP, Qin S, Cheng G, Feng J, Wang J, Cseh A, Peil B, Gibson N, Ehrnrooth E, Zhang L. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. Onco Targets Ther. 2018 Nov 30;11:8565-8573. doi: 10.2147/OTT.S161506. eCollection 2018.
Results Reference
derived
PubMed Identifier
29902295
Citation
Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Goker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fulop A, Buhnemann C, Gibson N, Kramer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.
Results Reference
derived
PubMed Identifier
28577938
Citation
Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Goker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Buhnemann C, Kramer N, Solca F, Ehrnrooth E, Ardizzoni A. Evaluation of the VeriStrat(R) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.
Results Reference
derived
PubMed Identifier
26156651
Citation
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Goker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info
Learn more about this trial
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
We'll reach out to this number within 24 hrs